Missing IMP Destruction Certificates in Regulatory Audit Reports

Posted on August 31, 2025 By digi

Published on 23/12/2025

Why Missing IMP Destruction Certificates Are Cited in Regulatory Audit Findings

Table of Contents

Toggle

Introduction: IMP Destruction as a Compliance Requirement

Investigational Medicinal Products (IMPs) must be destroyed in accordance with regulatory requirements and protocol specifications once they are expired, damaged, or no longer required for a trial. Regulatory authorities such as the FDA, EMA, and MHRA expect destruction to be documented with signed certificates to demonstrate accountability. Missing IMP destruction certificates are a recurring regulatory audit finding, raising concerns about compliance, product diversion, and patient safety risks.

Destruction certificates provide documented proof that unused or expired IMPs were disposed of in a controlled and compliant manner. Their absence undermines regulatory confidence, compromises audit trails, and exposes sponsors to potential violations under ICH GCP and national laws governing investigational products.

Regulatory Expectations for IMP Destruction Documentation

Authorities define specific requirements for IMP destruction:

• IMPs must be destroyed in compliance with national regulations and site SOPs.
• Destruction activities must be documented in signed and dated certificates.
• Certificates must specify lot numbers, quantities destroyed,

Continue Reading

and method of destruction.

Destruction records must be archived in the Trial Master File (TMF) for inspection readiness.

Sponsors must verify destruction documentation during monitoring visits and audits.

The Health Canada Clinical Trials Database emphasizes proper IMP destruction documentation as part of trial accountability and regulatory transparency.

Common Audit Findings on Missing Destruction Certificates

1. Absent or Incomplete Certificates

Auditors often find that destruction certificates are missing or incomplete, lacking details such as lot numbers or quantities destroyed.

2. Missing Signatures

Inspection reports frequently highlight unsigned or undated certificates, undermining their validity.

3. Inconsistent Documentation

Auditors cite discrepancies between IMP accountability logs and destruction records.

4. Sponsor Oversight Failures

Sponsors are often cited for failing to verify whether sites or CROs maintained proper destruction documentation.

Case Study: FDA Audit on IMP Destruction

During a Phase II oncology trial, FDA inspectors discovered that over 200 vials of expired IMP were destroyed without any signed destruction certificates. The site reported that the destruction was “locally managed,” but no supporting records were available. The finding was categorized as a critical deficiency, requiring immediate corrective actions and resubmission of accountability records.

Root Causes of Missing IMP Destruction Certificates

Root cause analyses of audit findings often identify:

• Absence of SOPs specifying destruction documentation requirements.
• Poor coordination between sites, CROs, and destruction vendors.
• Failure of sponsors to verify site-level destruction documentation.
• Reliance on verbal confirmation instead of documented evidence.
• Lack of training for staff handling IMP destruction procedures.

Corrective and Preventive Actions (CAPA)

Corrective Actions

• Collect retrospective destruction documentation from sites and vendors.
• Update TMF with complete destruction certificates for all IMPs.
• Retrain staff on destruction documentation requirements and validation.

Preventive Actions

• Develop SOPs mandating signed certificates for all IMP destruction activities.
• Ensure destruction vendors are qualified and maintain compliant documentation.
• Verify destruction certificates during monitoring visits and audits.
• Integrate destruction documentation into electronic IMP accountability systems.
• Conduct periodic sponsor audits of destruction activities at sites and vendors.

Sample IMP Destruction Certificate Log

The following dummy table illustrates how destruction documentation can be structured:

Best Practices for Preventing Missing Certificate Findings

To minimize audit risks, sponsors and sites should adopt these practices:

• Require destruction certificates as a mandatory element of IMP accountability.
• Maintain vendor qualification records and audit destruction vendors regularly.
• Verify destruction documentation at every monitoring visit.
• Store signed and validated certificates in the TMF for inspection readiness.
• Align destruction procedures with risk-based monitoring and sponsor oversight plans.

Conclusion: Ensuring Accountability in IMP Destruction

Missing IMP destruction certificates remain a recurring regulatory audit finding that undermines accountability and compliance. Regulators expect signed, complete, and inspection-ready destruction records as part of trial integrity.

Sponsors can prevent such findings by enforcing SOP-driven destruction processes, qualifying vendors, and maintaining oversight through monitoring and audits. Proper destruction documentation not only ensures compliance but also protects public trust and participant safety.

For further resources, see the EU Clinical Trials Register, which underscores the importance of documentation in investigational product management.